Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
SRG | Susceptibility Rapid Grower | No, (Bill Only) | Yes |
When this test is ordered, rapid grower susceptibility will be performed at an additional charge.
Minimum Inhibitory Concentration (MIC) by Microtiter Broth Dilution Method
Acid-Fast Bacilli (AFB)
AFB (Acid-Fast Bacilli)
Antibiotic Susceptibility
Bacillus, Acid-Fast
MIC (Minimum Inhibitory Concentration)
Minimum Inhibitory Concentration (MIC)
Mycobacteria Antimicrobial Susceptibility (MIC) (Minimum Inhibitory Concentration)
Mycobacterium abscessus Susceptibility Testing
Mycobacterium chelonae Susceptibility Testing
Mycobacterium fortuitum Susceptibility Testing
Mycobacterium mucogenicum Susceptibility Testing
Rapid Growing Mycobacteria to Antimicrobial Agents
Susceptibility Testing
Clofazimine
When this test is ordered, rapid grower susceptibility will be performed at an additional charge.
Varies
If organism identification is not provided, CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies must also be ordered and will be charged separately.
1. For shipping information see Infectious Specimen Shipping Guidelines
2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.
1. Specimen source is required.
2. Organism identification is required unless either CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies is also ordered.
3. Identification to the species level is required for Mycobacterium species for the correct antimicrobial susceptibility drug panel to be selected. Identification to the genus level is sufficient for Nocardia species and other aerobic actinomycetes (eg, Gordonia species, Rhodococcus species).
Question ID | Description | Answers |
---|---|---|
Q00M0038 | Specimen source (Required) and Organism Identification (Required unless concurrent identification test is ordered) |
Specimen Type: Organism
Supplies: Infectious Container, Large (T146)
Container/Tube: Middlebrook 7H10 agar slant or other appropriate media
Specimen Volume: Pure isolate
Collection Instructions:
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.
See Specimen Required
Agar plate | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Refrigerated |
Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel
When this test is ordered, rapid grower susceptibility will be performed at an additional charge.
There are more than 100 species of rapidly growing mycobacteria and many are significant human pathogens (eg, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum). Rapidly growing mycobacteria cause a variety of infections including pulmonary infections, skin and soft tissue infections, and disseminated disease. Antimicrobial susceptibility testing of clinically significant rapidly growing mycobacteria is important to help guide patient care.
Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.
Interpretive criteria and reporting guidelines are followed using the Clinical Laboratory Standards Institute (CLSI) M24S document.
Results are reported as the minimum inhibitory concentration in micrograms/mL. Interpretive criteria (susceptible, intermediate, or resistant) are reported according the Clinical and Laboratory Standards Institute guidelines.
1. Brown-Elliott BA, Pilley JV. Rapidly growing mycobacteria. Microbiol Spectr. 2017;5(1):1-19
2. Apiwattankul N, Flynn PM, Hayden RT, Adderson EE. Infections caused by rapidly growing mycobacteria spp in children and adolescents with cancer. J Pediatric Infect Dis Soc. 2015;4(2):104-113
3. Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015;36(1):67-78
The method employed in this assay is broth microtiter dilution using a commercially available RAPMYCO2 plate. Antimicrobials included in the assay are tested according to CLSI guidelines.(Clinical and Laboratory Standards Institute [CLSI]. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI standard M24. Clinical and Laboratory Standards Institute [CLSI]. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI supplement M24S)
Monday through Sunday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
87186
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
MMLRG | Susc, AFB, Rapidly Growing | 29579-0 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
MMLRG | Susc, AFB, Rapidly Growing | 29579-0 |